Aceclofenac

（提示：指南截图，文末可下载原文） 导语： 近年来，国内相继发布多部权威指南均统一推荐金字塔型阶梯化分级治疗策略，即基础治疗、药物治疗、修复性治疗、重建治疗，且明确基础治疗与药物治疗贯穿疾病全程，是OA全程管理的核心。 然而，在OA的治疗中存在非甾体抗炎药（NSAIDs）、糖皮质激素类药物的不合理使用以及过度治疗、药物滥用的现象。 为进一步规范骨关节炎临床用药，保障 OA 患者关节整体健康，中华医学会运动医疗分会联合中国医师协会骨科医师分会运动医学学组、关节镜学组，组织国内相关领域专家共同编撰《骨关节炎临床药物治疗专家共识》，以期指导临床安全、有效、经济地使用OA治疗药物。 01 关于骨关节炎 骨关节炎 (OA) 属于退行性关节病，以软骨破坏为核心，可引发疼痛、晨僵（持续时间极少超过30min）、关节畸形、活动受限; 65岁以上膝痛人群有超50%患病，75岁以上患病率超 80%; 临床首选X 线检查，参照 2018版OA指南及KL分级（见表1）完成诊断。 治疗目标：缓解疼痛，延缓疾病进展，矫正关节畸形，改善关节功能，提高患者生活质量。 02 OA药物治疗的关键地位 药物在 OA 整体治疗中地位关键，有症状患者需要短期或长期全程用药；治疗理念由较单一的抗炎、镇痛、缓解症状，转向多方位的改善病情。 3 OA治疗药物分类及属性 根据用药方式分为以下7类：局部外用药、口服药、肛门栓剂、肌内注射药、静脉注射药、关节腔内注射药及其他（如生物制剂等） 一、局部外用药 经皮肤局部渗透起效，全身暴露少、不良反应小，为优选治疗。 ✅ 适用：轻度 OA、高龄、基础病多、口服药胃肠不耐受者；中、重度OA可联用口服 NSAIDs。 ❌ 禁用：皮肤破损、皮疹、局部感染；出现过敏即刻停药。  分  类： 1. 外用NSAIDs 代表药物：双氯芬酸、洛索洛芬、酮洛芬、布洛芬等，剂型含贴剂、凝胶、乳膏、溶液、喷雾剂； 具体用法和用量见附表1。 2.非NSAIDs擦剂 通过提调控神经肽P物质的释放和储存而发挥镇痛和止痒效果，可缓解关节、肌肉疼痛，代表药物为辣椒碱外用制剂。 3.中药膏剂 多制成贴膏、药膏剂型，主打活血通络、补益肝肾、强筋健骨，可改善骨代谢、减轻关节疼痛。 4.外用麻醉剂  以芬太尼透皮贴为代表，适用于中重度慢性顽固性疼痛； 二、口服药 按作用分为：对症减轻症状、改善功能，延缓病情，抗骨质疏松，抗焦虑，中成药五大类。 1. 减轻症状、改善功能类 ● NSAIDs（口服）：OA 症状控制首选药物 ✅ 适用：有症状骨关节炎 ❌ 禁用：活动性消化道溃疡/出血、NSAIDs过敏、肝肾功能不全、严重高血压 / 心衰、血细胞减少、妊娠哺乳期女性。 分类： 非选择性 COX 抑制剂、选择性 COX2 抑制剂常用药物：阿司匹林、布洛芬、洛索洛芬、双氯芬酸、醋氯芬酸、美洛昔康、尼美舒利、艾瑞昔布、塞来昔布、依托考昔等，用法用量详见附表 2 ✅ 用药提示 (1) 优先选择可促进软骨蛋白聚糖合成药物：洛索洛芬、艾瑞昔布、塞来昔布、双氯芬酸、美洛昔康、醋氯芬酸； (2) 单药足量用 1-2 周无效再换药；禁止联用 2 种及以上 NSAIDs。 ⚠️不良反应与应对： 主要为胃肠道损伤：恶心腹痛，重者溃疡、出血、穿孔；可联用 PPI（奥美拉唑、兰索拉唑、泮托拉唑）护胃。 ● 对乙酰氨基酚 ✅ 适用：OA 轻、中度疼痛，胃肠肝肾相对安全 ❌ 禁用：过敏、严重肝肾功能不全 ✅ 用药提示：日剂量≤2g；老人、肝肾疾病、饮酒者剂量减半；疗效不佳可换用 NSAIDs ⚠️不良反应：偶发皮疹、粒细胞减少；长期大剂量可致肝肾损伤 ● 阿片类药物 机制：激动阿片受体，阻断疼痛信号传入中枢 ✅ 适用：仅用于 NSAIDs 禁忌或无效者；不推荐OA一线镇痛，成瘾及不良反应风险高 ❌ 禁用：哮喘、上呼吸道梗阻、严重肝肾损伤、颅内高压、不明急腹症、孕产期 / 哺乳期女性、1 岁以内婴儿 分类：强、弱阿片类，详见附表 3、附表 4 ✅ 用药提示：个体化，用最低有效剂量，禁止同类药物叠加使用 ⚠️不良反应：呼吸抑制、心悸、恶心，存在依赖风险 2. 延缓病情进展类● 双醋瑞因 机制：IL1 抑制剂，抑制软骨降解、促进软骨合成、减轻滑膜炎症，抗炎护软骨，延缓 OA 进展、缓解疼痛、改善关节功能 ✅ 适用：OA 慢性疼痛镇痛治疗 ❌ 禁用：本品或蒽醌衍生物过敏、过敏性结肠炎等肠道病史者 ✅ 用药提示：2至4周起效；初期可联用镇痛药 / NSAIDs；疗程不少于 3 个月● 氨基葡萄糖 机制：补充软骨原料，刺激软骨细胞生成蛋白多糖，促进滑膜分泌透明质酸 ✅ 适用：轻度 OA；终末期软骨严重磨损疗效差；疗效尚存争议，按需选择使用 ❌ 禁用：药物过敏者 ✅ 用药提示：分硫酸、盐酸型；硫酸型胃肠刺激更小、吸收更佳；需连续服用 8 周以上；餐中 / 餐后服用减轻胃肠刺激 3. 抗骨质疏松症类 OA与骨质疏松存在相关性，但研究结论仍存有争议。 4. 抗焦虑类 用于长期持续性OA疼痛、NSAIDs 效果不佳患者；远期疗效有待观察，需专科医生指导下使用。 5. 中成药 多靶点发挥作用，可缓解疼痛、延缓 OA 进展、改善关节功能。 三、肛门栓剂 特点：吸收快、起效迅速 ✅ 适用：不便于口服用药的 OA 患者 ❌ 禁用：活动性消化道溃疡 / 出血、重度心力衰竭患者 常用药物：NSAIDs（吲哚美辛栓等） 四、肌内注射药 ✅ 适用：无法静脉给药、其他治疗效果不佳的患者 常用药物：盐酸布桂嗪、曲马多等阿片类制剂 五、静脉注射药 ✅ 适用：无法口服、其他给药方式疗效不佳者 特点：起效快、剂量易调整；应遵循能口服不静滴原则 常用药物：帕瑞昔布钠、氟比洛芬酯、阿片类药物 六、关节腔内注射药 核心作用：快速缓解关节疼痛、改善关节功能，常用药物包括糖皮质激素、医用几丁糖、玻璃酸钠。 ❌ 禁忌：感染性关节炎、全身/局部感染、凝血功能异常、药物过敏及其他不适宜注射的情况。1. 糖皮质激素 机制：降低血管通透性，减轻关节充血、渗出及炎症浸润，快速抗炎镇痛 ✅ 适用：改善早期轻度OA关节肿痛，对重度OA剧痛效果有限 ❌ 禁忌：激素过敏、全身各类感染、严重精神疾病、活动性消化溃疡、严重高血压、糖尿病等 ✅ 用药提示：同一关节每年最多不超过2~3次，注射间隔时间不应短于3~6个月，避免频繁使用 ⚠️不良反应：反复注射会损伤关节软骨 2. 医用几丁糖 机制：调控软骨细胞代谢、减轻炎症，补充关节液、延缓OA进展 ✅ 适用：轻、中度骨关节炎患者 ❌ 禁忌：严重关节畸形、重度创伤性关节炎、出血性关节炎 ✅ 用药提示：每疗程注射2~3次，每年1~2个疗程 ⚠️不良反应：偶见局部红肿、发热、过敏反应 3. 玻璃酸钠 机制：关节润滑、保护软骨与半月板、抗炎镇痛、促进软骨修复及内源性透明质酸分泌 ✅ 适用：全身多关节轻、中度OA；尤其适合老年、有胃肠/心脑血管病史人群，可减少口服镇痛药用量及相关不良反应 ❌ 禁忌/慎用：关节局部感染、不明关节积液肿胀；禽蛋过敏者慎用 ✅ 用药提示：每周1次，3~5周为一疗程，每年1~2个疗程 ⚠️不良反应：注射后轻微关节肿痛、积液，大多可自行缓解 七、生物制剂 1. 富血小板血浆（PRP） 机制：富含多种生长因子、抗炎因子，可保护软骨、促进软骨修复、减轻关节炎症； ✅ 适用：年轻、轻中度退行性改变、有症状的OA患者效果更佳； ❌ 禁忌：注射区皮肤破损/病变、不明关节大量积液、凝血异常、败血症； ✅ 用药提示：单次注射3–5 ml，间隔1–3周，2–3次为一疗程； ⚠️不良反应：局部疼痛、红肿，罕见关节内感染。 2. IL‑1受体拮抗剂 核心价值：IL‑1是导致软骨破坏的关键因子，该类制剂可拮抗IL‑1、改善软骨；结构，具备逆转OA损伤潜力； 现状：整体仍处于临床探索阶段，尚未普及常规治疗； 3. 抗炎性细胞因子制剂 作用：抑制IL‑1β、TNF‑α等炎症因子释放；； 前景：为OA精准靶向治疗提供新型研究方向； 4. 间充质干细胞 机制：可分化为成骨、软骨细胞，修复受损骨与软骨组织； 现状：已应用于OA治疗，但远期疗效与安全性仍需更多临床研究验证； 4 OA用药基本原则 核心治疗目标：镇痛、改善关节功能、延缓病情、提升生活质量。 核心用药原则：根据病变分期、疼痛程度、病灶位置，采取阶梯化、个体化、内外联用方案，以口服NSAIDs、病情改善类药物为核心治疗药物。 一、不同分期、不同病变的治疗原则及药物选择 1. 无症状/轻微症状（K-L Ⅰ级） 临床表现：偶发关节痛，无肿胀畸形，日常活动正常，仅见轻微骨赘、关节间隙可疑狭窄。 ✅ 推荐方案：以健康教育、功能锻炼等基础治疗为主；症状无改善，外用NSAIDs、中药乳膏局部镇痛。 ❌ 不推荐：常规使用全身口服镇痛药；局部用药无效后，可经医生评估换用或联用口服药。 2. 轻度OA（K-L Ⅱ级） 临床表现：频繁关节痛，基本不影响活动，偶有关节肿胀，无畸形，存在轻度关节间隙狭窄、少量骨赘。 ✅ 推荐方案：药物治疗为主、结合基础治疗！ 对乙酰氨基酚无效者，选用小剂量、短疗程NSAIDs，优先局部用药，剧痛可内外联用； 老年患者选短半衰期NSAIDs；有消化道病史者优选选择性COX-2抑制剂； 联用双醋瑞因、氨基葡萄糖等软骨保护剂，可关节腔注射玻璃酸钠、医用几丁糖； ❌ 不推荐：口服阿片类药物、关节腔注射糖皮质激素 3. 中度OA（K-L Ⅲ级） 临床表现：反复关节疼痛、活动受限，频繁关节肿胀，可出现关节畸形，关节间隙明显狭窄、中等量骨赘。 ✅ 推荐方案：口服NSAIDs为首选，需长期服药！ 优先选用COX-2抑制剂，或联用PPI保护胃黏膜，搭配软骨保护剂延缓病情； 合并软骨损伤、半月板问题，可术后注射玻璃酸钠、医用几丁糖修复关节； 中重度疼痛慎用关节腔糖皮质激素； ❌ 不推荐：口服阿片类药物（成瘾、安全风险高）4. 重度OA（K-L Ⅳ级） 临床表现：剧烈持续疼痛、活动严重受限，关节反复肿胀、严重畸形，关节间隙重度狭窄、骨赘大量形成、软骨下骨病变。 ✅ 推荐方案：治疗方法包括关节置换，药物治疗，镇痛首选NSAIDs！ 优先COX-2抑制剂或联用PPI，降低胃肠损伤风险； 阿片类药物仅可围手术期短期使用，严禁长期应用； ❌ 不推荐：软骨保护剂、病情改善药（软骨严重损伤，基本无效），关节腔注射糖皮质激素不推荐使用。 二、个体化用药 1.合并基础疾病 （1）心血管疾病 ● 总体原则：心血管高危人群，慎用心血管风险较高的药物，优先选择安全系数更高的品种； ● 优选NSAIDs：艾瑞昔布、塞来昔布、依托考昔，心血管风险更低，可搭配小剂量阿司匹林保护心血管； ● 合并高血压：酌情选用上述低风险NSAIDs，规律降压、监测血压并动态调量；服药期间每7–10天复查肾功能； （2）合并糖尿病● 首选方案：优先使用外用NSAIDs；● 用药谨慎：2型糖尿病合并重度脂肪肝、肝炎患者慎用对乙酰氨基酚；糖尿病肾病高危人群慎用口服NSAIDs； ● 安全推荐：双醋瑞因、玻璃酸钠、医用几丁糖，不影响血糖代谢，可正常使用； ● 治疗建议：可合理联用软骨保护剂、延缓病情药物。 （3）消化道疾病 ● 核心原则：消化道高危人群，慎用胃肠刺激性强的药物; ● 药物优选：优先选用选择性NSAIDs，相较非选择性药物，溃疡风险更低; ●用药方式：NSAIDs需餐后服用，减少胃肠损伤; ● 高危预防：高风险患者推荐联用PPI（奥美拉唑等）、米索前列醇，预防消化道溃疡、出血等并发症; ● 不推荐：组胺受体拮抗剂，防护效果不佳。 2. 肥胖 ● 风险关系：肥胖是 OA 重要独立危险因素；OA 亦可加重肥胖、炎症及心血管疾病风险； ● 干预重点：健康宣教、自我管理、适度运动、体重管控。3. 年龄 ● 老年OA患者用药提示  ①用最小有效剂量、缩短疗程，优先局部用药，监测不良反应； ②留意药物相互作用，根据病情及时调整方案；  ③肝肾功能减退，酌情减量。 ● 年轻 OA 患者 尽早去除诱因：半月板撕裂、关节骨折、下肢力线异常等； 及早使用软骨保护 / 延缓病情药物，保护软骨、维持关节功能。 三、用药注意事项 ● 外用制剂：皮肤破损、皮疹、感染慎用；发生过敏立即停药；  ● 对乙酰氨基酚：过敏、严重肝肾功能不全禁用；饮酒、老年人群剂量减半； NSAIDs：个体化给药，采用最低有效剂量、短疗程，优先局部用药，必要时联用 PPI 护胃；  ● NSAIDs 禁忌：活动性消化道溃疡 / 出血、NSAIDs 过敏、肝肾功能不全、严重高血压、心衰、血细胞减少、妊娠哺乳期，禁用或慎用； ● 糖皮质激素：关节创伤、出血、感染禁用；与 NSAIDs 合用会升高消化道出血风险；  ● 关节腔注射（玻璃酸钠 / 医用几丁糖）：关节或穿刺部位感染、凝血异常、出血性关节炎、严重创伤性关节炎、不明关节肿胀积液、严重关节畸形，禁止注射； ● 双醋瑞因：24 周起效，初期可联用镇痛药 / NSAIDs；  ● 长期疼痛伴情绪受影响，可选用抗焦虑药物；  ● 机制相近药物不可叠加使用；疗效不佳应换药，减少不良反应风险。 05 骨关节炎临床药物治疗专家共识条目 (1) 早期OA的非药物治疗非常关键，包括健康教育、控制好体重、合理锻炼、 (2) 自我管理、物理治疗等。 (3) 外用NSAIDs可作为OA早期药物治疗的首选，尤其适用于合并胃肠道疾病、心血管疾病或身体虚弱的患者，对小关节、肩锁关节、膝关节、肘关节等OA有效。 (4) 口服NSAIDs适用于中、重度OA患者，推荐使用对胃肠道不良反应小的NSAIDs，但需警惕其心血管不良事件。 (5) 由于阿片类镇痛剂的不良反应和成瘾性发生率相对较高，不推荐其作为OA镇痛的首选药物。 (6) 糖皮质激素短期缓解OA肿痛效果显著，但不宜反复多次使用。 (7) 关节腔内注射玻璃酸钠和医用几丁糖适用于轻、中度OA患者。 (8) 关节腔内注射PRP适用于轻、中度OA患者。 (9) 氨基葡萄糖对有症状的OA患者可选择性使用。 (10)在OA用药过程中，遵循能外用不口服、能口服不注射、能注射不手术的原则，依据OA不同程度，进行个体化、阶梯化的系统合理用药治疗。 06 结语 有症状 OA 需积极干预，药物治疗重在镇痛、改善关节功能、延缓病程、提升生活质量。依据个体情况、发病部位、病情分期，采取内外结合、个体化、阶梯化系统治疗。 药物选择、联合方案、剂量疗程，需兼顾安全性与有效性，做到科学合理用药。 中华医学会运动医疗分会，中国医师协会骨科医师分会运动医学学组. 骨关节炎临床药物治疗专家共识[J].中国医学前沿杂志（电子版), 2021, 13 (7):32-43 END 扫描二维码阅读 /下载原文 本篇为转载，版权属作者所有，如有侵权请联系删除。  编辑：仇书海、李瑞娜；校对：；审核：尹河   往期推荐 “白脉”到底是什么？你的身体里有张神秘的“能量网” 醋酸钙 vs 碳酸钙，同是“钙”字辈，区别为什么这么大！ 旋风跑出加速度，业绩翻番拦不住！集团公司这场拓展，燃爆了！

Patients with "bone-on-bone" arthritis, PRP produced sustained pain and function and measurable shifts in cartilage breakdown. A knee replacement is a wonderful operation, but it is major, irreversible surgery with a finite lifespan, and the younger you have it, the more likely you are to outlive it.” — Gurpreet Singh Padda, MD ST. LOUIS, MO, UNITED STATES, July 19, 2026 / EINPresswire.com / -- Randomized Trial in Patients Already on the Knee Replacement Waiting List Finds Platelet-Rich Plasma Outperformed Cortisone and Anti-Inflammatories — Including in Blood Chemistry In 90 patients with "bone-on-bone" arthritis, PRP produced sustained pain and function gains at six months, lower opioid use, and measurable shifts in cartilage breakdown and inflammatory biomarkers. St. Louis physician Gurpreet Padda, MD: "We are not regrowing your cartilage — and the honest version is still the better story." A randomized controlled trial accepted for publication in the Journal of Orthopedic Surgery and Research has reported that two injections of autologous platelet-rich plasma (PRP) outperformed both corticosteroid injection and oral anti-inflammatory medication in patients with late-stage knee osteoarthritis — and did so not only on pain and function scores, but on serum markers of inflammation and cartilage breakdown. The trial is notable for who it enrolled. All 90 participants had Kellgren-Lawrence grade 3 or 4 disease — the radiographic stages routinely described to patients as "bone-on-bone" — and all were already on the waiting list for total knee replacement. This is the population most biologic injection trials exclude. Gurpreet Padda, MD, MBA, who directs the regenerative and metabolic medicine practice, Regen.MD in St. Louis has built patient and physician education around the findings. "There's a sentence said in exam rooms every day: you're bone on bone, there's nothing left to do, we just have to replace it," said Dr. Padda. "That sentence is a lie — not a malicious one. Most of the doctors who say it genuinely believe it. But it's built on a way of thinking about the body that is decades out of date, and the data directly contradict that way of thinking. These were not easy early cases. These were the patients everyone had already given up on, sitting on a surgical waiting list." What the Trial Found Lacko and colleagues at P. J. Šafárik University and L. Pasteur University Hospital in Košice, Slovakia, enrolled 90 patients aged 40 to 80 between September 2024 and June 2025, randomizing them to three arms: two intra-articular injections of non-activated autologous PRP one week apart; a single intra-articular betamethasone (corticosteroid) injection; or oral aceclofenac, an NSAID. Patients were followed for six months, with clinical scores and a 13-marker serum biomarker panel measured at baseline, three months, and six months. Eighty-two patients completed follow-up. Pain. Visual analog scale scores fell significantly only in the PRP group, from 6.2 at baseline to 3.3 at three months, holding at 3.7 at six months. The corticosteroid group moved from 6.3 to 5.8, and the NSAID group from 6.3 to 5.8 — neither a statistically significant change from baseline. Between-group differences favored PRP at three months (p<0.001 versus both controls) and six months (p=0.004 versus corticosteroid; p=0.002 versus NSAID). Function and stiffness. Total WOMAC scores improved only in the PRP arm, from 49.0 to 28.1 at three months and 32.5 at six months, with significant gains across pain, stiffness, and function subscales. Corticosteroid scores were essentially unchanged at 45.6, and the NSAID group deteriorated, from 48.8 at baseline to 57.9 at six months. Opioid use. Rescue opioid consumption, standardized to morphine milligram equivalents, was lowest in the PRP group — significantly lower than corticosteroid at both three months (p=0.002) and six months (p=0.006), and lower than NSAID at three months (p=0.025). Dropouts. No patient in the PRP arm withdrew. Two corticosteroid patients and four NSAID patients discontinued after three months because their pain was never adequately controlled, and proceeded to earlier total knee replacement. Two additional NSAID patients were withdrawn after worsening ischemic heart disease. Biomarkers. Compared with the corticosteroid group at three months, PRP patients showed significant reductions in the cartilage-turnover and inflammatory markers COMP (p=0.015), MMP-3 (p=0.024), IL-6 (p=0.035), IL-18 (p=0.037), and TNF-α (p=0.017), alongside increases in the anti-inflammatory and anabolic markers sTREM2 (p=0.019), sRAGE (p=0.017), and TGF-β1 (p=0.048). CGRP — a neuropeptide associated with peripheral pain sensitization — was significantly lower in the PRP group than in both controls (p=0.032 and p=0.024). Reductions in COMP, IL-6, and IL-18 were still present at six months. Safety. Three PRP patients experienced transient knee pain and swelling that resolved within one day. No other adverse events were recorded in the PRP arm. The authors' stated conclusion is that PRP is supported as "a safe bridge therapy before arthroplasty." The Line Regen.MD Insists On Dr. Padda's educational materials make one limitation non-negotiable. "We are not regrowing your cartilage. The gap on your X-ray is not going to close," Dr. Padda said. "PRP is not a magic serum that reverses structural damage, and anyone promising you a brand-new joint from an injection is selling a fantasy that will cost you money and hope. The RESTORE trial in JAMA showed that in milder osteoarthritis, PRP did not regrow cartilage or beat placebo in terms of structure. That finding is real, and I respect it. How do I hold both truths? Pain and structure are decoupled. We are not changing the architecture of the knee. We are changing its biology — and in advanced disease, that biological change is what produced measured relief. I would rather tell you a smaller true thing than a bigger false one." What the Trial Does Not Establish Regen.MD's materials present the study's limitations alongside its results. The investigators state that participants were not blinded to their assigned intervention; that the three arms differed in route of administration, dosing frequency, and overall treatment intensity, which limits direct comparability; and that the PRP product was not quantitatively characterized in this trial. It was a single-center study. The NSAID arm had a substantial dropout rate due to adverse effects and inadequate pain control. Biomarker analyses were exploratory, and no correction for multiple comparisons was applied. No structural imaging endpoint was assessed, and the trial makes no claim of cartilage regrowth. It also did not measure how many patients ultimately avoided or deferred surgery — the only surgical events recorded were the six control-arm patients who proceeded to earlier replacement. Converging Evidence on Treating the Bone Itself A second randomized controlled trial, published in the Journal of Clinical Medicine in November 2025, addressed a related question in the same severity range. Sánchez Santiuste and colleagues randomized 86 patients with Kellgren-Lawrence grade III–IV knee osteoarthritis in a double-blind multicenter design. All patients received intra-articular Plasma Rich in Growth Factors; the arms differed by whether they also received an intraosseous infiltration into the subchondral bone, or an intraosseous saline placebo. The intraosseous group improved significantly more across nearly all domains at 3, 6, and 12 months, with 66.7% reaching minimum clinically important improvement in pain versus 46.3% (p=0.0038). No serious adverse events occurred. That trial likewise assessed no structural imaging, and PRGF is a specific leukocyte-poor preparation whose results do not automatically transfer to other platelet systems. "The objection to biologics in advanced arthritis was always anatomical, and it sounded reasonable: there's no cartilage left, so what are you signaling to," Dr. Padda said. "But in an end-stage knee, the subchondral bone is not inert scaffolding. It's edematous, hypervascular, densely innervated, and remodeling badly, and it generates a substantial share of the pain. Treating only the joint space in a grade IV knee means treating the one compartment where the disease has already finished its work." Regen.MD performs both intra-articular and intraosseous PRP. Service Availability at Regen.MD The practice's orthobiologics program provides image-guided biologic procedures, including intra-articular and tendon PRP in leukocyte-poor and leukocyte-rich preparations, intraosseous/subchondral PRP, bone marrow aspirate concentrate (BMAC), adipose-derived Lipogems grafts, and intradiscal orthobiologics. Every needle is placed under ultrasound or fluoroscopic guidance rather than by anatomical landmark, and diagnostic blocks are used to confirm the pain generator before a biologic is deployed. The practice's published indication for subchondral treatment is the joint that still hurts after a technically correct intra-articular injection. As its service materials put it, MRI bone-marrow lesions — edema in the subchondral bone beneath a worn surface — track closely with pain and progression, "and a joint-space injection never reaches them." Under fluoroscopic guidance, platelet concentrate is delivered through the cortex into the subchondral bone itself, typically paired with an intra-articular dose — the same combination tested in the Sánchez Santiuste trial. Regen.MD's published protocol emphasizes matching the preparation to the tissue — leukocyte-rich for tendon, leukocyte-poor for intra-articular and subchondral use — and treating the injectate as a biological drug prepared to a measured therapeutic threshold. The practice's stated position is that "PRP is not one product, and most failures start here," and that "a perfect biologic in the wrong tissue plane is an expensive placebo." Procedures are paired with the practice's work in metabolic inflammation and its laboratory-guided peptide therapy program, on the rationale that a repair signal delivered into an inflamed, insulin-resistant environment is unlikely to hold. The practice treats chronic back pain, joint dysfunction, metabolic inflammation, and neuropathic pain, and describes its diagnostic sequence in Our Approach. Regen.MD's joint dysfunction materials note that many patients carrying the bone-on-bone label retain more functional cartilage than the term implies, that radiographic narrowing correlates only loosely with reported pain, and that roughly one in five knee replacement patients reports persistent pain after surgery. Related patient education is available in The Library , including "Bone on Bone Knee?" Why "Nothing Can Be Done" Is a Lie: Is Meniscus Surgery Worth It? What 10-Year Data Reveals, Orthobiologics in St. Louis: Repairing the System Instead of Silencing the Alarm, and Intradiscal PRP: The Protocol for Treating the Disc as Biology, Not Hardware. Further material appears in the Surgery Alternatives and Regenerative Treatments collections and under Patient Resources. How to Begin Regen.MD does not offer free consultations or introductory calls. Patients begin with a Clinical Evaluation — a structured diagnostic assessment that includes imaging review, ultrasound examination, and metabolic laboratory work — with a $400 non-refundable fee, initiated through the clinical application at regen.md. "Come and get a real evaluation," Dr. Padda said. "Let us look at your knee and your biology and tell you honestly whether you're a candidate for a regenerative bridge, or whether replacement really is your best next step. Either way, you finally have the truth and a choice. A knee replacement is a wonderful operation, but it is major, irreversible surgery with a finite lifespan, and the younger you have it, the more likely you are to outlive it. What the data offers is control of the timeline — the ability to decide when, or whether. A bridge isn't a smaller thing than a miracle. Sometimes it's the whole thing." About Regen.MD Regen.MD is a regenerative and metabolic medicine practice in St. Louis, Missouri, led by Gurpreet Padda, MD, MBA, who has worked for three decades at the intersection of interventional pain management, regenerative medicine, and metabolic biology. The practice treats chronic back pain, joint dysfunction, metabolic inflammation, and neuropathic pain through image-guided orthobiologic procedures — including intra-articular and intraosseous PRP — alongside laboratory-guided peptide protocols and metabolic optimization. Regen.MD is located at 4477 Woodson Rd, Suite 103, St. Louis, MO 63134, near St. Louis Lambert International Airport. Gurpreet Singh Padda, MD Regen.MD +1 314-668-1525 email us here Visit us on social media: YouTube The Lie of the End of the Road: Bone on Bone Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.